TGF-B1 Expression in Colorectal Tumors and Its Prognostic Value
Author Information
Author(s): H Robson, E Anderson, RD James, PF Schofield
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Can TGF-B1 expression serve as an independent prognostic marker in colorectal cancer?
Conclusion
TGF-B1 expression is associated with poorer survival outcomes in colorectal cancer patients.
Supporting Evidence
- TGF-B1 was expressed in 58.3% of tumors and was associated with advanced Dukes' stage.
- Patients with TGF-B1-positive tumors had a 3-year survival rate of only 40%, compared to 80% for TGF-B1-negative tumors.
- The presence of TGF-B1 was significantly correlated with shorter post-operative survival, especially in patients who had palliative operations.
Takeaway
This study found that a protein called TGF-B1 in colorectal tumors can help doctors predict how well patients will do after treatment.
Methodology
Immunohistochemical analysis of TGF-B1 and LAP-TGF-B1 expression in colorectal tumor specimens from 72 patients.
Limitations
The study may not account for all variables affecting survival, and the sample size is relatively small.
Participant Demographics
Patients aged 32-92 years, with a mean age of 70; more males than females.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website